electroCore, Inc. (ECOR)

NASDAQ: ECOR · IEX Real-Time Price · USD
0.371
+0.007 (1.98%)
At close: Feb 3, 2023, 4:00 PM
0.360
-0.011 (-2.94%)
After-hours: Feb 3, 2023, 7:39 PM EST
1.98%
Market Cap 26.40M
Revenue (ttm) 7.52M
Net Income (ttm) -21.32M
Shares Out 71.17M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 154,012
Open 0.390
Previous Close 0.364
Day's Range 0.370 - 0.390
52-Week Range 0.195 - 0.700
Beta 0.93
Analysts Buy
Price Target 2.51 (+576.73%)
Earnings Date Mar 8, 2023

About ECOR

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaw... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 52
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2021, electroCore's revenue was $5.45 million, an increase of 55.93% compared to the previous year's $3.50 million. Losses were -$17.22 million, -26.77% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ECOR stock is "Buy." The 12-month stock price forecast is $2.51, which is an increase of 576.73% from the latest price.

Price Target
$2.51
(576.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

electroCore Announces Issuance of Two New U.S. Patents

ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Offic...

2 months ago - GlobeNewsWire

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been...

2 months ago - GlobeNewsWire

electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan G...

2 months ago - GlobeNewsWire

electroCore Announces Third Quarter 2022 Financial Results

Third quarter 2022 revenue grew 33% over third quarter 2021

3 months ago - GlobeNewsWire

electroCore Provides Select Third Quarter 2022 Financial Guidance

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary finan...

4 months ago - GlobeNewsWire

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices Four patents issued expanding claims related to delivery of nVNS and other therapies using mob...

4 months ago - GlobeNewsWire

electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference

ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan G...

6 months ago - GlobeNewsWire

electroCore to Announce Second Quarter 2022 Financial Results on August 4

ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the sec...

6 months ago - GlobeNewsWire

electroCore Provides Select Second Quarter 2022 Financial Guidance

ROCKAWAY, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary finan...

7 months ago - GlobeNewsWire

electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome

ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiat...

7 months ago - GlobeNewsWire

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus ne...

9 months ago - GlobeNewsWire

electroCore to Participate at Upcoming Investor Conferences

ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Go...

9 months ago - GlobeNewsWire

electroCore Announces Record First Quarter 2022 Financial Results

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially

9 months ago - GlobeNewsWire

electroCore Completes Sale of New Jersey Tax Benefits

ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its available ...

10 months ago - GlobeNewsWire

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published result...

10 months ago - GlobeNewsWire

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for furth...

10 months ago - GlobeNewsWire

electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York

ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medica...

11 months ago - GlobeNewsWire

electroCore to Present at 2022 Maxim Virtual Growth Conference

ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Execut...

11 months ago - GlobeNewsWire

electroCore Announces Fourth Quarter and Full Year 2021 Financial Results

Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020

11 months ago - GlobeNewsWire

electroCore Announces Changes to its Board of Directors

Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding sig...

11 months ago - GlobeNewsWire

electroCore to Present at 34th Annual Roth Conference

ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will b...

11 months ago - GlobeNewsWire

electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022

Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Tr...

1 year ago - GlobeNewsWire

ECOR Stock Alert: Why Is electroCore Soaring Today?

electroCore skyrocketed today after the FDA gave its PTSD treatment a breakthrough designation. ECOR stock closed up 60% on the news!

1 year ago - InvestorPlace

ElectroCore's Vagus Nerve Stimulator Wins Breakthrough Device Tag For Stress Disorder

The FDA has granted Breakthrough Designation to ElectroCore Inc's (NASDAQ:ECOR) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of PTSD by 31%...

1 year ago - Benzinga